Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.35 |
| ▸ | EGFR | P00533 | 2/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | TDO2 | P48775 | 1/20 | 0.33 |
| ▸ | SNCA | P37840 | 1/20 | 0.32 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.32 |
| ▸ | LPL | P06858 | 4/20 | 0.32 |
| ▸ | LIPG | Q9Y5X9 | 4/20 | 0.32 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.32 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.32 |
| ▸ | ALPL | P05186 | 1/20 | 0.32 |
| ▸ | GSK3A | P49840 | 1/20 | 0.30 |
| ▸ | GSK3B | P49841 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1368949 | 0.80 | EGFR (0.39) | DGAT1EGFRIDO1TDO2SNCA | |
| SCHEMBL29545777 | 0.80 | EGFR (0.39) | DGAT1EGFRIDO1TDO2SNCA | |
| SCHEMBL30161251 | 0.80 | DGAT1 (0.41) | DGAT1FFAR1HIF1AIDO1TDO2 | |
| SCHEMBL21864818 | 0.80 | DGAT1 (0.41) | DGAT1FFAR1HIF1AIDO1TDO2 | |
| SCHEMBL20445835 | 0.79 | RPS6KB1 (0.48) | — | |
| SCHEMBL20445801 | 0.79 | RPS6KB1 (0.48) | — | |
| SCHEMBL25455442 | 0.76 | DGAT1 (0.43) | DGAT1FFAR1AAK1HIF1APRMT5 | |
| SCHEMBL20445792 | 0.75 | RPS6KB1 (0.52) | EGFRIDO1TDO2 | |
| SCHEMBL20445793 | 0.75 | RPS6KB1 (0.52) | EGFRIDO1TDO2 | |
| SCHEMBL24744297 | 0.72 | EGFR (0.43) | EGFRIDO1TDO2SNCAIRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230143059-A1 | GCN2 MODULATOR COMPOUNDS | Alesta Therapeutics BV (NL) | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230143059-A1 | GCN2 MODULATOR COMPOUNDS | EIF2AK4, GPR119, GCN1 | DGAT1 864/4885FFAR1 321/4885AAK1 1582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.